Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma

This publication has 14 references indexed in Scilit:

• The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27
  Journal of Clinical Oncology, 2003
• Neoadjuvant Docetaxel in Breast Cancer: 3-Year Survival Results from the Aberdeen Trial
  Clinical Breast Cancer, 2002
• Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902
  Journal of Clinical Oncology, 2001
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000
• Maximized Reduction of Primary Breast Tumor Size Using Preoperative Chemotherapy With Doxorubicin and Docetaxel
  Journal of Clinical Oncology, 1999
• Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy
  Journal of Clinical Oncology, 1999
• Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up
  Annals of Oncology, 1999
• Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
  Journal of Clinical Oncology, 1998
• A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer
  British Journal of Cancer, 1996
• Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6
  European Journal Of Cancer, 1994